{"id":"W4293367557","doi":"10.1002/cpdd.1153","title":"Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton‐Pump Inhibitors","year":2022,"lang":"en","type":"article","venue":"Clinical Pharmacology in Drug Development","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada)","funders":"","keywords":"Bioavailability; Pharmacokinetics; Medicine; Pharmacology; Tolerability; Bioequivalence; Chemistry; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002821132,0.0004100896,0.001179423,0.0003597982,0.0003039278,0.0007774556,0.0004502021,0.0007970409,0.001885996],"category_scores_gemma":[0.002627357,0.0002871786,0.0009953271,0.0005347438,0.0005146195,0.0006194096,0.0002625771,0.001150143,0.0002959266],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004089409,"about_ca_system_score_gemma":0.0006268313,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001045333,"about_ca_topic_score_gemma":0.0007617275,"domain_scores_codex":[0.9976036,0.00126459,0.0001593523,0.0003551893,0.0005139433,0.0001033197],"domain_scores_gemma":[0.9990327,0.0002514012,0.0002989908,0.0001140518,0.0001858878,0.0001168923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2038981,0.01770402,0.006555654,0.001289537,0.001926089,0.0002094518,0.0006637878,0.002636863,0.6686315,0.001021683,0.00135506,0.09410823],"study_design_scores_gemma":[0.02844338,0.7023322,0.05405485,0.0001075887,0.003348733,0.0008522392,0.0002598434,0.01522823,0.1812079,0.0004061494,0.01360899,0.0001499505],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9921938,0.001672101,0.003828291,0.0000744069,0.00009907545,0.0008229133,0.0003939824,0.0000546746,0.0008606309],"genre_scores_gemma":[0.9948318,0.0005401553,0.003018276,0.00007673333,0.00006921591,0.0005233607,0.0003087429,0.0000176884,0.0006139355],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002821132,"threshold_uncertainty_score":0.01491976,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2395849207718664,"score_gpt":0.4805594073694024,"score_spread":0.240974486597536,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}